BioSpace News Archive

The growth of the global soft tissue repair market is attributed to the rising prevalence of sport injuries, and increasing number of orthopedic procedures.

The market is estimated to grow with a CAGR of 6.5% from 2020 to 2027.

INmune Bio, Inc., a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announced that the Company has entered into a new $15 million credit facility with Silicon Valley Bank and an affiliate of SVB Financial Group.

PDS Biotechnology Corporation, a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune® T-cell activating technology, announced that it has commenced an underwritten public offering of shares of its common stock.

RAPT Therapeutics, Inc., a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, announced that it has commenced an underwritten public offering of $125 million of its common stock.

Seqirus, a global leader in influenza prevention and a division of CSL Limited (ASX: CSL), today announced that the company co-authored the first study to demonstrate the safety, immunogenicity and efficacy profile of a COVID-19 vaccine when co-administered with a seasonal influenza vaccine

Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities General Regulation, Innate Pharma SA releases its total number of shares outstanding as well as its voting rights as of June 1, 2021

Calibre Scientific is pleased to announce the acquisition of LINARIS Biologische Produkte GmbH, a life science distributor with headquarters outside of Frankfurt, Germany.

TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapeutics, announces that it has submitted an IND for its Phase I trial of immunotherapeutic TILT-123 in ovarian cancer.

Masimo announced the findings of a study published in the Turkish Journal of Medical Sciences in which Dr. Ayten Saracoglu and colleagues at the Marmara University Pendik Training and Research Hospital in Istanbul evaluated the ability of ORi to guide oxygenation by measuring its impact on hyperoxemia-mediated morbidity during one-lung ventilation conducted as part of thoracic surgery.